“We have a $5 billion market cap now. The next stage is for us to get to $20 billion,” declares the chief executive of the Chinese biotech highlighted in today’s article, whose “steadfast mission [is] to become a global oncology business, and revolutionize cancer treatment by creating a portfolio of drugs aimed at preventing the disease from multiple angles through combining different therapies.” For more on this company – whose shares are dual-listed in the UK and on the Nasdaq, and which Goldman Sachs analysts rate as a Buy – CLICK HERE.